Poster
p-Tau 217 is considered the most accurate single plasma biomarker for detecting amyloid pathology. Recently, expert workgroups have recommended that p-Tau 217 tests be designed with two cut-offs in recognition of signal overlap between diseased and non-diseased subjects1,2. Two cutoffs maximize the accuracy of the test but leaves a diagnostic intermediate zone with uncertainty of amyloid status. It is desirable to minimize the indeterminant zone to reduce the number of patients receiving uncertain results. We investigated whether the inclusion of plasma amyloid beta 42/40 ratio, NfL, and GFAP into a multi-marker logistic regression model including p-Tau 217 would enable amyloid classification of uncertain results from p-Tau 217 alone. Download our poster to learn more.
[1] Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimer’s Dement. 2024; 1-27.
[2] Schindler, S.E., Galasko, D., Pereira, A.C. et al. Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease. Nat Rev Neurol 20, 426–439 (2024).